PA
OCUL icon

Profund Advisors’s Ocular Therapeutix OCUL Stock Holding History

Profund Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
33,201
+5,451
+20% +$49.4K 0.01% 754
2026
Q1 		$235K Buy
27,750
+7,941
+40% +$75.7K 0.01% 928
2025
Q4 		$240K Sell
19,809
-5,369
-21% -$65.2K 0.01% 1042
2025
Q3 		$294K Buy
25,178
+2,272
+10% +$27.2K 0.01% 745
2025
Q2 		$213K Buy
22,906
+6,993
+44% +$54.7K 0.01% 868
2025
Q1 		$117K Sell
15,913
-4,608
-22% -$35.4K 0.01% 939
2024
Q4 		$175K Sell
20,521
-1,836
-8% -$17.9K 0.01% 1030
2024
Q3 		$195K Sell
22,357
-20,825
-48% -$172K 0.01% 1059
2024
Q2 		$295K Buy
43,182
+31,314
+264% +$193K 0.01% 726
2024
Q1 		$108K Buy
+11,868
New +$84.2K ﹤0.01% 1124
2023
Q4 		– Sell
-20,827
Closed -$65.4K – 1149
2023
Q3 		$65.4K Buy
20,827
+10,099
+94% +$41.3K ﹤0.01% 954
2023
Q2 		$55.4K Buy
+10,728
New +$63.8K ﹤0.01% 1058

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Profund Advisors's OCUL Position: Q2 2026 in Review

Profund Advisors increased its Ocular Therapeutix (OCUL) stake by 20% in Q2 2026, buying an estimated $49.4K and bringing the position to 33,201 shares worth $326K. The position accounts for 0.01% of the portfolio, ranked #754.

Profund Advisors first reported a position in OCUL in Q2 2023 and has held it in 12 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Profund Advisors held 33,201 shares of Ocular Therapeutix worth $326K as of Q2 2026.
  • Profund Advisors bought 5,451 Ocular Therapeutix shares in Q2 2026, an estimated $49.4K.
  • Ocular Therapeutix made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #754 holding.
  • Profund Advisors first reported a position in Ocular Therapeutix in Q2 2023 and has held it in 12 quarters since.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.